FTY720 Shows Promising In vitro and In vivo Preclinical Activity by Downmodulating Cyclin D1 and Phospho-Akt in Mantle Cell Lymphoma

PURPOSE: Despite the progress that has been made in the treatment of mantle cell lymphoma (MCL), all patients invariably relapse with the currently available therapies. Because of the absence of curative therapy for MCL, we explored FTY720 as a novel agent against MCL. EXPERIMENTAL DESIGN: The cytot...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Liu, Qing, Alinari, Lapo, Chen, Ching-Shih, Yan, Fengting, Dalton, James T., Lapalombella, Rosa, Zhang, Xiaoli, Mani, Rajeswaran, Lin, Teresa, Byrd, John C., Baiocchi, Robert A., Muthusamy, Natarajan
Formato: Artigo
Lenguaje:Inglês
Publicado: 2010
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4180653/
https://ncbi.nlm.nih.gov/pubmed/20460491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-09-2484
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares